title: Infection Rate and Risk Factors in Patients Treated With Azacitidine.
authors.affiliation: Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain. Electronic address: orero_may@gva.es.
authors.forename: M
authors.initials: M
authors.lastname: Orero
authors.affiliation: Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Villegas
authors.affiliation: Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Ortiz
authors.affiliation: Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.
authors.forename: K P
authors.initials: KP
authors.lastname: Javier
authors.affiliation: Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Costa
authors.affiliation: Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.
authors.forename: P L
authors.initials: PL
authors.lastname: Pérez
authors.affiliation: Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Roig
authors.affiliation: Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Linares
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000209:etiology*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D014777:Virus Diseases / Q000209:etiology*
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine